Peptide News Digest

Survodutide SYNCHRONIZE-1 16.6% Phase 3 Topline, Boehringer BI 3034701 Triple Agonist, Boston Peptide Summit, Three Nature Peptide Papers

Boehringer/Zealand Survodutide SYNCHRONIZE-1 hits 16.6% weight loss at 76 weeks; BI 3034701 triple agonist heads to Phase 2; Boston peptide summit opens; Nature peptide papers.

10 stories · Covering clinical-trials, regulatory, industry, research

Editor's Note

Today's headline is Boehringer Ingelheim and Zealand Pharma's Phase 3 SYNCHRONIZE-1 readout for survodutide — 16.6% weight loss vs 3.2% placebo at 76 weeks, predominantly fat-mass loss, with up to 85.1% of treated adults achieving ≥5% weight reduction. The drug is now positioned as the third meaningful entrant in the obesity GLP-1-class market, with full data slated for ADA 2026 in June. Boehringer paired the announcement with another piece of news: BI 3034701, a Gubra-originated first-in-class triple GLP-1/GIP/NPY2 agonist, is heading to Phase 2 mid-2026. On the broader peptide front, FormBlends' 2026 State of Peptides report mapped the post-FDA-Category-2 regulatory landscape, the 3rd Peptide-Based Therapeutics Summit opened today in Boston (April 28-30) with Pinnacle Medicines, Unnatural Products, and Daiichi Sankyo as featured speakers, and three peptide-focused research papers landed in Nature journals: a Viola-derived peptide asparaginyl ligase study expanding cyclic-peptide synthesis tools, a DDA-BERT transformer model for peptide identification, and the engineering of genetically encoded CRAC channel inhibitory binders.

Clinical Trials

Boehringer Ingelheim and Zealand Pharma Announce Phase 3 SYNCHRONIZE-1 Topline: Survodutide Achieves 16.6% Weight Loss at 76 Weeks

Boehringer Ingelheim and Zealand Pharma announced positive topline results from the Phase 3 SYNCHRONIZE-1 trial of survodutide (BI 456906), a glucagon/GLP-1 dual agonist, in adults with obesity or overweight without type 2 diabetes. Adults treated with survodutide achieved 16.6% mean weight loss at 76 weeks (efficacy estimand) versus 3.2% placebo (p<0.0001), with up to 85.1% of treated adults achieving ≥5% weight reduction. Up to 39.2 lb (17.8 kg) average weight loss; initial analysis indicates predominantly fat-tissue loss with lean mass contributing only a small proportion. Full data will be presented at ADA 2026 in June.

#boehringer-ingelheim #zealand-pharma #survodutide #synchronize-1 #glucagon-glp-1 #phase-3
Clinical Trials

Boehringer Advances BI 3034701: Gubra-Originated First-in-Class Triple GLP-1/GIP/NPY2 Agonist Heading to Phase 2 in Mid-2026

Boehringer Ingelheim disclosed alongside the survodutide topline that BI 3034701, a first-in-class triple GLP-1/GIP/NPY2 receptor agonist peptide, will enter Phase 2 in mid-2026. The compound completed a randomized placebo-controlled Phase 1 study in healthy volunteers and people with overweight/obesity that demonstrated favorable safety and tolerability and encouraging weight loss. BI 3034701 was developed in collaboration with Gubra, with Boehringer responsible for further development and global commercialization. The novel NPY2 component targets satiety pathways complementary to incretin agonism — a meaningful mechanistic differentiation in the next-gen obesity pipeline.

#boehringer-ingelheim #gubra #bi-3034701 #triple-agonist #npy2 #phase-2
Regulatory

FormBlends Releases 2026 State of Peptides and GLP-1 Regulation Report Tracking Post-Category-2 Landscape

FormBlends, a telehealth platform focused on medically supervised GLP-1 and peptide therapy, released its 2026 State of Peptides and GLP-1 Regulation Report on April 28. The report maps how RFK Jr.'s HHS, the FDA Center for Drug Evaluation and Research, and the next-generation obesity pipeline from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping legal access for weight management, metabolic health, and peptide therapy through the end of the decade. The report follows the April 22 formal removal of 12 peptides from FDA Category 2 and previews the July 23-24 PCAC meeting.

#formblends #state-of-peptides #fda #rfk-jr #compounding #policy-landscape
Industry

3rd Peptide-Based Therapeutics Summit Opens in Boston (April 28-30) with Pinnacle, Unnatural Products, Daiichi Sankyo as Featured Speakers

The 3rd Peptide-Based Therapeutics Summit opened today in Boston, running April 28-30 with the industry's only dedicated platform for next-generation peptide discoveries. Featured industry news being presented includes Pinnacle Medicines' $89M Series B for oral peptide therapeutics, J&J's FDA approval of ICOTRYDE™, Daiichi Sankyo's Meddenovo Mexa AI cyclic peptide collaboration, and Unnatural Products' $45M Series B for synthetic macrocyclic peptides (on top of last year's $1.7B Novartis deal). The summit reflects the rapid growth of peptides as a disruptive third modality alongside small molecules and biologics.

#peptide-summit #boston #industry-event #pinnacle #daiichi #unnatural-products
Industry

Pinnacle Medicines Featured at Boston Summit: $89M Series B Backs Oral Peptides With Injectable Biologic-Level Efficacy

OrbiMed-incubated Pinnacle Medicines is featured at the Boston peptide summit highlighting its oversubscribed $89M Series B financing (closed March 26) for advancing oral peptide therapeutics designed to match the efficacy of injectable biologics. Lead programs target asthma, COPD, immunology, and inflammation — distinct from the GLP-1 obesity focus dominating peptide headlines. The platform combines proprietary peptide stabilization with oral-bioavailability engineering, positioning Pinnacle as one of the most differentiated non-GLP-1 oral peptide developers in the current pipeline.

#pinnacle-medicines #oral-peptide #orbimed #asthma #copd #immunology
Industry

Daiichi Sankyo + Meddenovo Mexa AI Collaboration: De Novo Cyclic Peptide Design Featured at Boston Summit

Daiichi Sankyo's collaboration with Meddenovo's AI-powered Mexa technology — for de novo design of cyclic peptides — is among the highlighted partnerships at the Boston peptide summit. The deal positions Daiichi to leverage Meddenovo's machine-learning platform for peptide candidates beyond the company's traditional small-molecule oncology focus. Cyclic peptide AI design is one of the fastest-moving subcategories in peptide drug discovery, with Circle Pharma, Bicycle Therapeutics, and Unnatural Products all pursuing distinct platform architectures.

#daiichi-sankyo #meddenovo #mexa-ai #cyclic-peptide #de-novo-design #ai-drug-discovery
Research

Nature Communications: 29 New Peptide Asparaginyl Ligases Discovered from Viola Plants — Major Cyclic Peptide Synthesis Toolkit Expansion

A Nature Communications paper published April 27 mined natural diversity in Viola plants to discover 29 new peptide asparaginyl ligases (PALs) — enzymes that catalyze cyclization of synthetic peptide chains. The work characterizes a pH-dependent cyclization mechanism and defines transferable expression-increasing principles, substantially expanding the enzymatic toolkit available for cyclic peptide drug development. The discovery is timely given the surge of macrocyclic peptide programs at Circle Pharma, Bicycle Therapeutics, and Unnatural Products.

#peptide-asparaginyl-ligase #pal #viola #cyclic-peptide #nature-communications #biocatalysis
Research

Nature Communications: DDA-BERT Transformer Model Improves Peptide Identification Across Species and HLA Immunopeptidomics

A Nature Communications paper published April 27 introduced DDA-BERT, an end-to-end transformer-based deep learning model for peptide identification in data-dependent acquisition (DDA) proteomics. The model improves peptide identification accuracy across multiple species and outperforms existing methods on HLA immunopeptidomics — directly relevant to neoantigen peptide vaccine discovery for personalized cancer immunotherapy. The work joins the broader 2026 wave of AI-driven peptide tooling captured in this month's ACS Biochemistry and Nature Biotechnology papers.

#dda-bert #transformer #peptide-identification #proteomics #hla-immunopeptidomics #nature-communications
Research

Nature Biotechnology: User-Defined Peptide Libraries Enable Sensitive Detection of Cancer Antigens

A Nature Biotechnology paper introduced a user-defined peptide library platform that enables sensitive detection of cancer antigens — relevant for both cancer immunotherapy target identification and neoantigen vaccine design. The platform allows researchers to design peptide pools customized to specific tumor types or HLA profiles, accelerating the antigen-discovery bottleneck in personalized cancer vaccine development. Builds on the same proteomic technology stack advancing across multiple peptide-vaccine programs at BioNTech, Genentech, and emerging neoantigen biotechs.

#nature-biotechnology #cancer-antigen #peptide-library #neoantigen #tumor-immunology #vaccine-discovery
Research

Nature Communications: Engineered CRAC Channel Inhibitory Binders (CRABs) Open New Therapeutic Class for Channelopathies and Cancer Immunology

A Nature Communications paper introduced genetically encoded CRAC (calcium release-activated calcium) channel inhibitory binders — designated CRABs — derived from the ORAI C-terminal tail. Membrane-anchored CRAB variants potently inhibit Ca²⁺ influx and downstream NFAT signaling, offering a peptide-based modulator class for channelopathies, autoimmune disorders, and cancer immunotherapy applications. The mechanism complements existing CRAC channel small-molecule inhibitors and expands the toolkit for precision modulation of calcium signaling.

#crab #crac-channel #calcium-signaling #orai #nature-communications #channelopathy